Home/Filings/4/0000950170-24-027261
4//SEC Filing

Stewart Richard Alistair 4

Accession 0000950170-24-027261

CIK 0000949858other

Filed

Mar 5, 7:00 PM ET

Accepted

Mar 6, 4:49 PM ET

Size

7.6 KB

Accession

0000950170-24-027261

Insider Transaction Report

Form 4
Period: 2024-03-04
Stewart Richard Alistair
DirectorChieve Executive Officer
Transactions
  • Purchase

    Common Stock Warrants (right to buy)

    2024-03-04+10,00010,000 total
    Exercise: $4.91From: 2024-03-04Common Stock (10,000 underlying)
  • Purchase

    Common Stock

    2024-03-04$4.58/sh+10,000$45,85038,501 total
Footnotes (1)
  • [F1]The common shares reported on this Form 4 were purchased in a registered direct offering (the "RDO") at a price of $4.585, for an aggregate purchase price of $45,850 pursuant to a Securities Purchase Agreement (the "SPA") dated February 28, 2024. The SPA also provides for a concurrent private placement of warrants to purchase common shares (the "Private Placement Warrants") . The Private Placement Warrants are exercisable immediately upon issuance until the earlier of (x) three and one-half years after the date of issuance, and (y) 30 days following the Issuer's public disclosure of the acceptance of an NDA for cytisinicline by the FDA in a Day 74 Letter or equivalent correspondence.

Documents

1 file

Issuer

ACHIEVE LIFE SCIENCES, INC.

CIK 0000949858

Entity typeother

Related Parties

1
  • filerCIK 0001713369

Filing Metadata

Form type
4
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 4:49 PM ET
Size
7.6 KB